X2S1 Stock Chart & Stats
€8.50
€0.15(1.56%)
At close: 4:00 PM EDT
€8.50
€0.15(1.56%)
Day’s Range― - ―
52-Week Range€8.05 - €11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€5.18B
Enterprise Value€23.42K
Total Cash (Recent Filing)€41.90B
Total Debt (Recent Filing)€113.83B
Price to Earnings (P/E)5.6
Beta0.22
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.15
Shares Outstanding268,362,150
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio-4.41
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Nationwide Healthcare Distribution NetworkA nationwide distribution network gives Sinopharm broad access to institutional and retail healthcare customers. Its coverage across hospitals, clinics, pharmacies, and downstream distributors provides a durable operating platform for recurring product sales and related supply-chain services.
Diversified Healthcare Product PortfolioExposure to pharmaceuticals, devices, diagnostics, and consumables reduces reliance on a single healthcare category. This breadth allows the company to serve varied provider needs and supports more durable revenue opportunities across China’s healthcare distribution system.
Positive Cash GenerationPositive operating and free cash flow, together with cash conversion covering most net income, indicates that reported earnings generally translate into usable funds. This supports ongoing operations and gives Sinopharm some capacity to manage investment and financial obligations.
Bears Say
Recent Revenue ContractionRevenue declines in consecutive recent periods indicate that growth has lost momentum after stronger performance in 2021–2023. Continued contraction could limit operating leverage, reduce reinvestment capacity, and make future earnings increasingly dependent on efficiency gains.
Margin CompressionLower gross and EBITDA margins show that profitability has weakened within the distribution model. Thin margins leave less room to absorb pricing pressure or cost increases, while sustained compression could constrain earnings growth even if product volumes stabilize.
Higher Leverage And Lower ReturnsThe sharp increase in debt relative to equity reduces financial flexibility and raises the burden carried by future cash flows. At the same time, lower ROE suggests that the larger capital base is producing weaker returns, limiting the efficiency of future expansion.
Sinopharm Group Co News
X2S1 FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
Sinopharm Group Co lowest stock price was €8.05 and its highest was €11.80 in the past 12 months.
What is Sinopharm Group Co’s market cap?
Sinopharm Group Co’s market cap is €5.18B.
When is Sinopharm Group Co’s upcoming earnings report date?
Sinopharm Group Co’s upcoming earnings report date is Nov 02, 2026 which is in 32 days.
How were Sinopharm Group Co’s earnings last quarter?
Sinopharm Group Co released its earnings results on Aug 23, 2026. The company reported €0.699 earnings per share for the quarter.
Is Sinopharm Group Co overvalued?
According to Wall Street analysts Sinopharm Group Co’s price is currently Overvalued.
Does Sinopharm Group Co pay dividends?
Sinopharm Group Co does not currently pay dividends.
What is Sinopharm Group Co’s EPS estimate?
Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Group Co have?
Sinopharm Group Co has 268,362,150 shares outstanding.
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Sinopharm Group Co reported an EPS of €0.699 in its last earnings report. Following the earnings report the stock price went down -0.875%.
Which hedge fund is a major shareholder of Sinopharm Group Co?
Currently, no hedge funds are holding shares in DE:X2S1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinopharm Group Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.38%
12-Months-Change
Fundamentals
Return on Equity
5.27%
Trailing 12-Months
Asset Growth
1.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharmaceutical Distribution segment is responsible for supplying a wide array of pharmaceutical products to various healthcare entities, including hospitals, clinics, and retail pharmacies. This segment also provides comprehensive logistics and value-added services to both domestic and international manufacturers and suppliers of pharmaceutical and healthcare items. The Medical Devices segment focuses specifically on the distribution of medical equipment. Through its Retail Pharmacy segment, the company operates and franchises an extensive chain of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment encompasses the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core activities, Sinopharm Group also engages in property rental and management, distributes specialized products such as Chinese herbal medicines, antibiotics, and biological products, and offers a suite of services. These include IT development, medicine, business, health, and market information consulting, international trade (import/export of goods and technology), market investigation, and convention and exhibition services. Furthermore, the company is involved in medical project investment, consulting, and technology training. To enhance its commercial capabilities and transformation, Sinopharm Group Co. Ltd. maintains a strategic partnership with I-Mab. Founded in 2003, the company is headquartered in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.